Cambridgeshire
The alkaloid pilocarpine in therapeutic concentration of 0.5% to 4% was the first line treatment for POAG for over one hundred years following its introduction by Weber in 1876. 7 The most widely held expla nation of its action is that it simulates acetyl choline release at the neuromusclar junction of the parasympathetic short ciliary nerves and ciliary muscle, tautening the scleral spur and opening the trabecular meshwork and Schlemm's canal thus facilitating aqueous 
Patients and Methods
The study group was taken from non-diabetic new referrals to the department. Twenty con secutive glaucoma suspects later proven to have bilateral POAG were tested with 0.1 % pilocarpine eye drops. Patients already on topical treatment or who had undergone pre vious eye surgery were rejected and tonometry was delayed until after the test.
The control group was taken from a non glaucomatous population with normal lOP.
Diabetics and those with a first degree family history of glaucoma were excluded. Subjects with dry eyes and corneal abnormalities were also excluded from both groups. Controls were selected by age and sex to match indi viduals of the experimental group. Age was matched within three years of date of birth.
All subjects in both groups were Caucasian.
The composition of each group is listed in Table II . 
Observations
Observations were made by the authors in the windowless outpatient clinic. The illumi- 
